Zomedica Corp.
Key Highlights
- Achieved record revenue of $10.5 million in Q4 2025 and $32.0 million for full-year 2025, marking 20 consecutive quarters of YoY growth.
- Maintained a strong 68% gross margin for the full year, indicating healthy profitability from core product sales.
- Improved adjusted core operating loss (Adjusted Non-GAAP EBITDA loss) to $17.1 million in 2025, down from $20.2 million in 2024, showing positive operational trend.
- Reduced operating expenses by 7% year-over-year, leading to the lowest cash burn since commercialization, and ended 2025 with a strong cash balance of $53.3 million.
- Strategic focus on accelerating global product adoption and achieving cash flow breakeven and profitability in 2026.
Event Analysis
Zomedica Corp. Reports Strong 2025 Financial Results, Eyes Profitability
Event Description (what happened) Zomedica Corp. (NYSE American: ZOM) announced strong financial results for the fourth quarter and full year ended December 31, 2025. These results highlight significant growth and operational efficiency as the company moves closer to profitability, offering a crucial update on its financial health and strategic path.
Event Date/Timeline Zomedica announced its financial results for the fourth quarter and full year ended December 31, 2025, on March 16, 2026. The company will host a webinar on March 27, 2026, at 4:00 PM ET to discuss these results in more detail.
Impact Assessment (who/what is affected) Zomedica's strong financial performance reflects significant operational progress. The company sees sustained demand for its therapeutic devices, PulseVet® and Assisi®, and growing adoption of its TRUFORMA® diagnostic platform among veterinary professionals. This improved operational performance, combined with a strong cash position, creates a solid foundation for Zomedica's future. For 2026, the company plans to accelerate global product adoption and move towards cash flow breakeven and profitability, which will strengthen its long-term financial independence and market standing.
Financial Impact (if applicable)
- Record Revenue: Zomedica achieved a record $10.5 million in revenue for the fourth quarter of 2025, marking its first quarter exceeding $10 million. Full-year 2025 revenue reached $32.0 million, a robust 17% year-over-year increase. This extends their impressive streak to 20 consecutive quarters of year-over-year revenue growth. A new Development Services segment contributed $3.1 million in revenue, primarily in the second half of the year.
- Strong Gross Margin: The company maintained a healthy 68% gross margin for the full year, showing strong profitability from its core product sales.
- Improved Operational Performance: Zomedica reported a net loss of $81.9 million for the full year 2025. However, $55.8 million of this was a non-cash impairment charge – an accounting adjustment that does not involve actual cash outflow. Excluding this and other one-time items, the company's adjusted core operating loss (Adjusted Non-GAAP EBITDA loss) improved to $17.1 million in 2025, down from $20.2 million in 2024. This indicates a positive trend in the company's underlying business operations.
- Reduced Cash Burn & Strong Cash Position: Zomedica reduced operating expenses by 7% year-over-year, leading to the lowest cash burn since it began commercializing products. The company ended 2025 with a strong cash and cash equivalents balance of $53.3 million.
Key Takeaways for Investors These results show Zomedica's positive operational trajectory, marked by consistent revenue growth, strong gross margins, and significantly reduced cash burn. While the reported net loss includes a large non-cash impairment charge, the improved adjusted core operating loss (Adjusted Non-GAAP EBITDA loss) highlights the company's progress towards operational efficiency. Investors should recognize the company's clear strategic focus on global expansion and achieving profitability, which present both key challenges and opportunities. Zomedica will host a webinar on March 27, 2026, at 4:00 PM ET to delve deeper into these results and future plans, offering valuable insights. As always, investors are encouraged to conduct their own thorough research and consider the full financial picture.
Key Takeaways
- Zomedica demonstrates strong operational progress with consistent revenue growth, healthy gross margins, and significantly reduced cash burn.
- Investors should look beyond the reported net loss (which includes a large non-cash impairment charge) to the improved adjusted core operating loss, which highlights underlying business efficiency.
- The company has a clear strategic focus on global expansion and achieving cash flow breakeven and profitability in 2026, presenting significant future opportunities.
- A strong cash position of $53.3 million provides a solid foundation for future growth and strategic initiatives.
- The upcoming webinar on March 27, 2026, will offer valuable insights into the company's future plans and should be considered by investors.
Why This Matters
This event is highly significant for investors as it signals a strong positive trajectory for Zomedica. The company has achieved record revenues and demonstrated consistent year-over-year growth for 20 consecutive quarters, indicating robust market demand for its products like PulseVet®, Assisi®, and TRUFORMA®. Furthermore, the maintenance of a high 68% gross margin underscores the profitability of its core product sales, which is crucial for long-term financial health.
Beyond top-line growth, Zomedica has shown significant operational improvements. The reduction in adjusted core operating loss and a 7% decrease in operating expenses highlight effective cost management and a move towards greater efficiency. Ending the year with a strong cash position of $53.3 million provides a solid financial buffer to support its strategic initiatives, including global expansion and the stated goal of achieving cash flow breakeven and profitability in 2026. This financial stability and clear strategic direction can instill confidence in investors regarding the company's future viability and growth potential.
Financial Impact
Zomedica achieved record revenue of $10.5 million in Q4 2025 and $32.0 million for full-year 2025, a 17% year-over-year increase. The company maintained a strong 68% gross margin and improved its adjusted core operating loss to $17.1 million in 2025 from $20.2 million in 2024. Operating expenses were reduced by 7% YoY, and Zomedica ended 2025 with $53.3 million in cash and cash equivalents.
Affected Stakeholders
Learn More
About This Analysis
AI-powered summary derived from the original SEC filing.
Document Information
AI-Generated Analysis
This analysis is AI-generated from SEC filings. This is educational content, not financial advice. Always consult a financial advisor before making investment decisions.